Rhumbline Advisers Sells 1,049 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

Rhumbline Advisers decreased its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,901 shares of the company’s stock after selling 1,049 shares during the period. Rhumbline Advisers’ holdings in Astrana Health were worth $3,623,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ASTH. Janus Henderson Group PLC bought a new position in shares of Astrana Health in the third quarter valued at approximately $1,164,000. Royce & Associates LP bought a new position in shares of Astrana Health in the third quarter valued at approximately $6,661,000. Amalgamated Bank bought a new position in shares of Astrana Health in the third quarter valued at approximately $713,000. Principal Financial Group Inc. bought a new position in shares of Astrana Health in the third quarter valued at approximately $13,383,000. Finally, Loomis Sayles & Co. L P bought a new position in shares of Astrana Health in the third quarter valued at approximately $30,251,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Price Performance

ASTH stock opened at $25.38 on Friday. The company has a fifty day moving average price of $35.01 and a 200-day moving average price of $44.65. The company has a market capitalization of $1.43 billion, a P/E ratio of 19.52, a PEG ratio of 1.37 and a beta of 1.20. Astrana Health, Inc. has a 52-week low of $23.12 and a 52-week high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. As a group, equities analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.

Wall Street Analysts Forecast Growth

ASTH has been the subject of several research analyst reports. Truist Financial dropped their price objective on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, January 13th. Stifel Nicolaus dropped their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Robert W. Baird boosted their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Macquarie upgraded shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $65.60.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.